Shares of Coya Therapeutics Inc. COYA, 6.22% gained 12% premarket on Wednesday after the clinical-stage biotech company released new data from a study of its investigational therapy COYA 301 in patients with mild to moderate Alzheimer’s disease.
An open-label study in eight patients found a decrease in neuroinflammation following treatment with the therapy, the company said in a release. Coya previously reported that patients in the COYA 301 trial achieved a significant improvement in cognitive function.